Blurbs

Analysts’ Top Healthcare Picks: LivaNova (LIVN), Surface Oncology (SURF)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on LivaNova (LIVNResearch Report) and Surface Oncology (SURFResearch Report) with bullish sentiments.

LivaNova (LIVN)

Needham analyst Michael Matson reiterated a Buy rating on LivaNova today and set a price target of $77.00. The company’s shares closed last Wednesday at $47.55, close to its 52-week low of $41.82.

According to TipRanks.com, Matson is a 1-star analyst with an average return of -0.9% and a 44.1% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Merit Medical Systems.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for LivaNova with a $78.80 average price target, a 69.1% upside from current levels. In a report issued on October 19, Stifel Nicolaus also maintained a Buy rating on the stock with a $70.00 price target.

See today’s best-performing stocks on TipRanks >>

Surface Oncology (SURF)

JonesTrading analyst Soumit Roy reiterated a Buy rating on Surface Oncology today and set a price target of $6.00. The company’s shares closed last Wednesday at $1.26, close to its 52-week low of $0.92.

According to TipRanks.com, Roy is a 4-star analyst with an average return of 7.3% and a 33.0% success rate. Roy covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Deciphera Pharmaceuticals, and Adaptimmune Therapeutics.

Surface Oncology has an analyst consensus of Strong Buy, with a price target consensus of $9.38.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LIVN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More